NGL FINE-CHEM LIMITED

August 12, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Scrip Code: 524774

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No.C/1, G Block,
Bandra Kurla Complex, Bandra East,
Mumbai 400051.

Symbol: NGLFINE

Sub: Outcome of Board Meeting

Dear Sir/Madam,

We wish to inform you that, the Board of Directors of the Company at their meeting held today i.e. on **Wednesday, August 12, 2026** has inter-alia considered and approved the following:

1. **Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June, 30, 2026** pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 **along with Limited Review Report** of the Statutory Auditors thereon.

The meeting of the Board of Directors commenced at 4.50 p.m. and concluded at 5.20 p.m.

You are requested to kindly take the information on record.

Thanking you,

Yours faithfully,
For NGL Fine-Chem Limited

NGL FINE CHEM LIMITED

Shivam Gharat
Company Secretary and Compliance Officer
M. No.: A56704

Encl: As Above.

Regd. Office
301, E Square, Subhash Road,
Vile Parle (East), Mumbai- 400057,
Maharashtra, India

022-40842222
nglfinechem.com
info@nglfinechem.com
CIN: L24110MH1981PLC025884

MANEK & ASSOCIATES
CHARTERED ACCOUNTANTS
102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110
3158 5697
shailesh.manek@gmail.com
shailesh@camanek.com
www.camanek.com

SHAILESH MANEK
B.Com. (Hons), Grad. C.W.A., F.C.A.
Cell : +91 93222 26311

MITTUL B. DALAL
B.Com. F.C.A.
Cell : +91 80973 74277

Independent Auditor's Review Report on the unaudited quarter ended and year to date standalone financial results of M/s. NGL FINE-CHEM LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (as amended)

Review report to

The Board of Directors,

M/S. NGL FINE-CHEM LIMITED

1. We have reviewed the accompanying statement of Unaudited Financial results of **M/s. NGL Fine-Chem Limited ('the Company')** for the quarter ended **June 30, 2026** , and the year to date results from 1st April 2026 to 30th June, 2026 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 , as amended (the " Listing Regulations").

2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors at their respective meeting held on 12th August, 2026 has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("IND AS 34") " Interim Financial Reporting" prescribed under Section 133 of the Companies Act , 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015. Our responsibility is to express a conclusion on the Statement based on our review and other accounting principles generally accepted in India.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of company personnel, applying analytical and other review procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain

assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("IND AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**
Chartered Accountants
Firm's Registration No.:**126679W**

MBDalal

MANEK & ASSOCIATES CHARTERED ACCOUNTANTS FIRM No. 126679W MUMBAI-57.

(Mittul B Dalal)
Partner
Membership Number:172676
UDIN: **26172676ZGXXDU5417**

MUMBAI
Dated: **August 12, 2026**

MANEK & ASSOCIATES
CHARTERED ACCOUNTANTS
102, 1st Floor, 47 Avenue, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Offi. # 2618 5110
3158 5697
shailesh.manek@gmail.com
shailesh@camanek.com
www.camanek.com

SHAILESH MANEK
B.Com. (Hons), Grad. C.W.A., F.C.A.
Cell : +91 93222 26311

MITTUL B. DALAL
B.Com. F.C.A.
Cell : +91 80973 74277

Independent Auditor's Review Report on the unaudited quarter ended and year to date consolidated financial results of **M/S. NGL Fine-Chem Limited** pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Amended)

Review report to

The Board of Directors,

M/S. NGL Fine-Chem Limited.

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **M/S. NGL Fine-Chem Limited** ("the Parent") and its subsidiary **M/S. Macrotech Polychem Private Limited** (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income for the quarter ended **June 30, 2026** and the year to date results from 01st April 2026 to 30th June, 2026 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the " Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors and has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015. Our responsibility is to express a conclusion on the Statement based on our review and other accounting principles generally accepted in India.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial

information consists of making inquiries, primarily of company personnel, applying analytical and other review procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We have also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of M/s. Macrotech Polychem Private Limited, its wholly owned subsidiary.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Consolidated Financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard ("IND AS") specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MANEK & ASSOCIATES**
Chartered Accountants
Firm's Registration No.:**126679W**

MANEK & ASSOCIATES CHARTERED ACCOUNTANTS FIRM No. 126679W MUMBAI-57

MBDalal

(Mittul B Dalal)
Partner
Membership Number:**172676**
UDIN: **26172676CJHIOU1828**

MUMBAI
Dated : **August 12, 2026**

NGL FINE CHEM LIMITED

NGL FINE-CHEM LIMITED

Regd Office: 301 E Square, Subhash Road, Vile Parle (East), Mumbai 400 057, Maharashtra, India.

CIN: L24110MH1981PLC025884

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2026

Rupees in lakhs

	Particulars	Quarter ended			Year ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
I	Revenue from Operations	13,916.28	14,923.28	10,418.54	50,095.47
II	Other Income	742.81	245.92	635.35	1,472.82
III	Total Revenue (I+II)	14,659.09	15,169.20	11,053.89	51,568.29
IV	Expenses :				
	a) Cost of Material Consumed	8,047.42	6,729.93	5,540.20	24,721.78
	b) (Increase)/Decrease in stock in trade and work in progress	(1,905.68)	360.10	(351.02)	(772.72)
	c) Employee benefits expenses	1,891.76	1,695.98	1,576.14	6,550.08
	d) Finance Costs	98.51	100.76	122.20	446.75
	e) Depreciation and amortisation expenses	525.39	505.14	426.60	1,958.31
	f) Other expenses	3,554.02	3,996.04	2,555.82	12,327.32
	Total Expenses (IV)	12,211.42	13,387.95	9,869.94	45,231.52
V	Profit/(loss) before exceptional items and tax (III-IV)	2,447.68	1,781.25	1,183.95	6,336.77
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	2,447.68	1,781.25	1,183.95	6,336.77
VIII	Tax Expense				
	a) Current Tax	(445.00)	(690.00)	(130.00)	(1,688.00)
	b) Prior Years	-	82.68	(0.88)	81.80
	c) Deffered Tax	(162.96)	174.63	(129.01)	82.10
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	1,839.72	1,348.56	924.06	4,812.67
X	Other Comprehensive Income				
	a. Gain/(Loss) on actuarial valuation of post employment benefit	(48.21)	(12.46)	(32.71)	(32.38)
	b. Deferred tax on above	12.13	3.14	8.24	8.15
	c. Other Comprehensive Income (Net of Tax)	(36.08)	(9.33)	(24.47)	(24.23)
XI	Total Comprehensive Income	1,803.64	1,339.23	899.59	4,788.44
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- eacl	308.90	308.90	308.90	308.90
XIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	32,614.89
XIV	Earnings Per Share (EPS)				
	a) Basic	₹ 29.78	₹ 21.83	₹ 14.96	₹ 77.90
	b) Diluted	₹ 29.78	₹ 21.83	₹ 14.96	₹ 77.90

Notes:

1. The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 12th August 2026. These results were subjected to Limited Review by the Statutory Auditors of the Company.
2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time
3. The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
4. The consolidated results are for NGL Fine Chem Limited together with its 100% subsidiary Macrotech Polychem Private Limited.
5. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full year ended March 31, 2026 and the published year to date figures upto the the third quarter ended December 31, 2025 of the relevant financial year
6. Previous period figures have been regrouped/rearranged wherever necessary.

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2026

Rupees in lakhs

	Particulars	Quarter ended			Year ended
		30.06.2026 (Unaudited)	31.03.2026 (Audited)	30.06.2025 (Unaudited)	31.03.2026 (Audited)
I	Revenue from Operations	13,671.32	14,474.55	10,085.81	48,877.38
II	Other Income	735.67	251.18	655.34	1,485.24
III	Total Revenue (I+II)	14,406.99	14,725.73	10,741.15	50,362.62
IV	Expenses :				
	a) Cost of Material Consumed	8,161.46	6,806.64	5,506.91	24,963.49
	b) (Increase)/Decrease in stock in trade and work in progress	(1,893.95)	284.01	(405.19)	(839.03)
	c) Employee benefits expenses	1,749.36	1,569.44	1,447.00	6,025.46
	d) Finance Costs	96.81	99.48	120.83	440.16
	e) Depreciation and amortisation expenses	442.68	423.54	344.68	1,629.60
	f) Other expenses	3,676.12	4,055.09	2,755.45	12,680.89
	Total Expenses (IV)	12,232.48	13,238.20	9,769.68	44,900.57
V	Profit/(loss) before exceptional items and tax (III-IV)	2,174.51	1,487.53	971.47	5,462.05
VI	Exceptional Items	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	2,174.51	1,487.53	971.47	5,462.05
VIII	Tax Expense				
	a) Current Tax	(360.00)	(610.00)	(71.00)	(1,450.00)
	b) Prior Years	-	85.27	(0.88)	84.38
	c) Deffered Tax	(169.38)	172.63	(135.18)	66.79
IX	Profit/ (Loss) for the period from continuing operations (VII-VII	1,645.13	1,135.42	764.41	4,163.22
X	Other Comprehensive Income				
	a. Gain/(Loss) on actuarial valuation of post employment bene	(47.53)	(9.88)	(32.22)	(30.47)
	b. Deferred tax on above	11.96	2.49	8.11	7.67
	c. Other Comprehensive Income (Net of Tax)	(35.57)	(7.39)	(24.11)	(22.80)
XI	Total Comprehensive Income	1,609.56	1,128.03	740.30	4,140.42
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- e	308.90	308.90	308.90	308.90
XIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A	31,684.77
XIV	Earnings Per Share (EPS)				
	a) Basic	₹ 26.63	₹ 18.38	₹ 12.37	₹ 67.39
	b) Diluted	₹ 26.63	₹ 18.38	₹ 12.37	₹ 67.39

Notes:

1. The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Wednesday, 12th August 2026. These results were subjected to Limited Review by the Statutory Auditors of the Company.
2. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (IndAS prescribed under Section 133 of the Companies Act 2013 and read with the rules framed thereunder) and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time
3. The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
4. Previous period figures have been regrouped/rearranged wherever necessary.
5. The figures for the quarter ended March 31, 2026 are the balancing figures between the audited figures in respect of the full year ended March 31, 2026 and the published year to date figures upto the the third quarter ended December 31, 2025 of the relevant financial year
6. Previous period figures have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: August 12, 2026

NGL FINE CHEM LIMITED

For and On behalf of Board of Directors

Rahul Nachane
Managing Director
DIN 00223346